Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine vs ropivacaine TPVB for recovery after laparoscopic nephrectomy
ChiCTR2600129620Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liposomal bupivacaine in renal cell carcinoma (RCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Quality of recovery score at 24 hours postoperatively (QoR-15 total score). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2600129620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129620.